JFS Wealth Advisors’s Astrana Health ASTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$279 Buy
+6
New +$216 ﹤0.01% 2078
2025
Q3
Sell
-4
Closed -$100 1946
2025
Q2
$100 Hold
4
﹤0.01% 1811
2025
Q1
$125 Sell
4
-25
-86% -$833 ﹤0.01% 1866
2024
Q4
$915 Buy
29
+11
+61% +$522 ﹤0.01% 1685
2024
Q3
$1.04K Buy
18
+1
+6% +$49 ﹤0.01% 1687
2024
Q2
$690 Buy
17
+10
+143% +$397 ﹤0.01% 1754
2024
Q1
$294 Hold
7
﹤0.01% 1863
2023
Q4
$269 Sell
7
-1
-13% -$33 ﹤0.01% 1871
2023
Q3
$247 Sell
8
-2
-20% -$69 ﹤0.01% 1837
2023
Q2
$316 Buy
10
+1
+11% +$34 ﹤0.01% 1824
2023
Q1
$329 Buy
9
+7
+350% +$245 ﹤0.01% 1774
2022
Q4
$59 Sell
2
-7
-78% -$225 ﹤0.01% 1914
2022
Q3
$0 Buy
9
+5
+125% +$229 ﹤0.01% 1957
2022
Q2
$0 Sell
4
-1
-20% -$38 ﹤0.01% 1966
2022
Q1
$0 Buy
5
+3
+150% +$155 ﹤0.01% 1996
2021
Q4
$0 Buy
+2
New +$164 ﹤0.01% 1908

Other funds holding ASTH

JFS Wealth Advisors's ASTH Position: Q2 2026 in Review

JFS Wealth Advisors opened a new position in Astrana Health (ASTH) in Q2 2026: 6 shares worth $279. The stake represents ﹤0.01% of the portfolio and ranks #2078 among its holdings. This is a return to the name: JFS Wealth Advisors previously reported a position in ASTH as recently as Q2 2025.

JFS Wealth Advisors first reported a position in ASTH in Q4 2021 and has held it in 16 quarters since. The position peaked at $1.04K in Q3 2024. 209 funds tracked by Wall St. Rank hold ASTH as of Q2 2026.

  • JFS Wealth Advisors held 6 shares of Astrana Health worth $279 as of Q2 2026.
  • Astrana Health was a new JFS Wealth Advisors position in Q2 2026.
  • Astrana Health made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #2078 holding.
  • JFS Wealth Advisors first reported a position in Astrana Health in Q4 2021 and has held it in 16 quarters since.
  • JFS Wealth Advisors's Astrana Health position peaked at $1.04K in Q3 2024.
  • 209 funds tracked by Wall St. Rank held Astrana Health as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.